● The multi-stage, multi-year project is expected to be completed in ten years, with an estimated investment of $250m. ● The only project of its kind in sterile generic injectables in the last 30 years. ● The facility will be located in Pleasant Prairie, Wisconsin,...
Lincolnshire, Ill., February 21, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. “The launch further expands our generic injectable portfolio...
Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP,...
Lincolnshire, Ill., January 16, 2019 — Nexus Pharmaceuticals Inc. announced today the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL). “The FDA approval of...
Vernon Hills, IL., Nov. 15th, 2018 – Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals’ Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection. The product...
